Fierce Pharma

SEPTEMBER 18, 2024

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential blockbuster in tow. | Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. The crown jewel of the deal is undoubtedly Vtama, Dermavant’s steroid-free cream for plaque psoriasis, which is looking at a major expansion opportunity in eczema.

325

325

MedCity News

SEPTEMBER 17, 2024

Three-quarters of U.S. providers and payers say they have increased their IT spending over the past year, according to a new report from Bain & Company and KLAS Research. Both providers and payers are investing in cybersecurity technology, as well as AI tools. The post Providers and Payers Are Increasing Their Tech Spend — Where Are They Investing the Most?

Healthcare 137

Healthcare Healthcare 137

Authentic Influence Group

SEPTEMBER 16, 2024

The Silent Edge: How Body Language and Communication Skills Shape Leadership Success October 9, 2024 | 8:00 AM | NYC Free Event | Limited to 30 Seats Enjoy a Breakfast Bagel | Take in the NYC Skyline | Master Leadership Through Body Language Harness the power of what’s not being said. Join Shelly O’Donovan to master body language that transforms your leadership presence, influences decisions, and builds stronger teams.

Consulting 130

Consulting Training Competition Leads 130

pharmaphorum

SEPTEMBER 18, 2024

PBM Express Scripts has sued the FTC, claiming its recent report on the sector's role in drug pricing is defamatory and should be retracted

124

124

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

SEPTEMBER 19, 2024

A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migra | A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines.

Medicine 323

Medicine 323

MedCity News

SEPTEMBER 19, 2024

During a panel discussion at MedCity News’ INVEST Digital Health conference, three healthcare leaders shared their expert insight on what needs to change in order to improve the industry’s cybersecurity strategy. The post What Will It Take to Improve Healthcare Cybersecurity? appeared first on MedCity News.

Healthcare 132

Healthcare Healthcare 132

pharmaphorum

SEPTEMBER 16, 2024

FDA raps AbbVie for 'misleading' ad for migraine drug Ubrelvy featuring tennis star Serena Williams

FDA 119

FDA 119

Fierce Pharma

SEPTEMBER 20, 2024

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with the progressive disease suddenly have two new options, with more likely o | Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. With the nod, Dupixent becomes the first biologic treatment for COPD patients in the U.S.

FDA 321

FDA Patients 321

MedCity News

SEPTEMBER 19, 2024

Months after 23andMe CEO Anne Wojcicki publicly stated she wants to take the company she co-founded private, all of the company’s independent board directors have resigned. The board letter to Wojcicki stated that its members preferred resigning over continuing to have a difference of view over the direction of the company. The post Mass Board Exodus at 23andMe Leaves Company With Tough Decisions Ahead appeared first on MedCity News.

Government 128

Government Biopharma 128

Pharmaceutical Technology

SEPTEMBER 20, 2024

The growth of AI in the healthcare sector is already having real-world impacts and promises a step-change in future care.

Healthcare 115

Healthcare Healthcare 115

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

pharmaphorum

SEPTEMBER 20, 2024

Astellas is ready to launch its first digital health product in the US, called Digitiva, which provides at-home monitoring of people with heart failure

115

115

Fierce Pharma

SEPTEMBER 17, 2024

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.

FDA 323

FDA Marketing 323

MedCity News

SEPTEMBER 18, 2024

The current model of siloed, proprietary development is failing us. It’s slow, expensive, and often results in technologies that never see the light of day. What if, instead, we embraced an open-source approach to medical device innovation? The post The FDA Isn’t Blocking Medical Breakthroughs — Our Outdated Innovation Model Is appeared first on MedCity News.

Medical 128

Medical FDA 128

Pharmaceutical Technology

SEPTEMBER 20, 2024

The biotech has secured $65m in a Series A funding round led by Cormorant Asset Management and other investors.

Management 105

Management 105

Advertisement

pharmaphorum

SEPTEMBER 15, 2024

GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class

115

115

Fierce Pharma

SEPTEMBER 19, 2024

From truckloads of torn documents to avian incursions in the production plant, Granules India’s recent manufacturing reprimand from the FDA is alarming no matter which way you look at it. | Earlier this month, Granules was slapped with a Form 483 following an inspection of its Telangana facility in India that ran from Aug. 26 to Sept. 6. The FDA’s report cites six observations around poor quality control procedures, subpar cleaning, cross-contamination risks and more.

Manufacturing 320

Manufacturing FDA 320

MedCity News

SEPTEMBER 18, 2024

By acquiring Dermavant, Organon gets Vtama, a drug approved for treating plaque psoriasis. An FDA decision for the topical cream in atopic dermatitis is expected by the end of 2024. The post Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary appeared first on MedCity News.

FDA 128

FDA Biopharma Pharma 128

Pharmaceutical Technology

SEPTEMBER 19, 2024

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual differences in genes, environments, and lifestyles to drive better outcomes through medicine.

Medicine 105

Medicine Healthcare Healthcare Medical 105

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

SEPTEMBER 16, 2024

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia in a phase 2 trial presented at ESMO

Patients 114

Patients 114

Fierce Pharma

SEPTEMBER 18, 2024

This summer, GSK cut its yearly vaccine sales projection o | In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.

Sales 317

Sales 317

MedCity News

SEPTEMBER 20, 2024

Many are already experimenting with AI in narrow settings. But in order to expand deployment, it’s important to understand the most practical AI opportunities with the greatest ROI. Here are four high-impact opportunities that can boost staff efficiency and improve the patient experience. The post From Charting to Patient Intake: The 4 Biggest Opportunities for AI in Healthcare appeared first on MedCity News.

Healthcare 127

Healthcare Healthcare Patients 127

PharmaTimes

SEPTEMBER 18, 2024

It is hoped that the tool will improve the diagnostic pathway and free up radiologists’ time

Medical 104

Medical 104

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

SEPTEMBER 19, 2024

Neuralink gets FDA breakthrough status for an implantable chip called Blindsight that promises to restore eyesight to the blind

FDA 111

FDA 111

Fierce Pharma

SEPTEMBER 18, 2024

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 inhibitors have engaged in a spirited market battle, with one key differenc | Locked in a spirited market battle with GSK's Nucala, AstraZeneca's Fasenra is catching up with its IL-5 inhibitor rival as the FDA signed off on its use to treat the rare autoimmune condition of eosinophilic granulomatosis with polyangiitis.

FDA 316

FDA Marketing Patients 316

MedCity News

SEPTEMBER 16, 2024

It’s important that we focus attention on the areas where AI is already having a significant impact. These are the practical applications that will allow the best and brightest researchers to focus on science rather than data munging. The post We’re Overcomplicating Healthcare AI — Here’s How We Achieve Impact Beyond The Hype appeared first on MedCity News.

Healthcare 128

Healthcare Healthcare Electronics Medical 128

PharmaTimes

SEPTEMBER 16, 2024

The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex

101

101

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

pharmaphorum

SEPTEMBER 19, 2024

FDA turns down Vanda Pharma's tradipitant for gastroparesis, prompting a furious response from the company

FDA 111

FDA Pharma 111

Fierce Pharma

SEPTEMBER 17, 2024

With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán Bioscience is looking to bridge the gap between clinic and market for its cust | With a hefty investment led by Bain Capital and a new commercial facility on the horizon, growing CDMO Serán Bioscience is looking to bridge the gap between clinic and market for its customers.

Marketing 304

Marketing 304

MedCity News

SEPTEMBER 20, 2024

Zevra Therapeutics drug Miplyffa is now FDA approved for Niemann-Pick disease type C, a lysosomal storage disorder. The affirmative regulatory decision took into account additional clinical data generated since the FDA turned down a submission for the drug in 2021. The post FDA Approval Makes a Zevra Drug the First Therapy for Rare and Fatal Metabolic Disease appeared first on MedCity News.

FDA 126

FDA Biopharma Pharma 126

Pharmaceutical Technology

SEPTEMBER 18, 2024

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.

Sales 98

Sales Patients FDA 98

Advertisement

Distribution